Ads
related to: retinal stem cell clinical trials
Search results
Results from the WOW.Com Content Network
This therapy involves the transplantation of stem cells into the retina to replace damaged or lost retinal pigment epithelium (RPE) and photoreceptor cells, which are critical for central vision. Clinical trials have shown promise in stabilizing or improving visual function, but are nevertheless inefficient. [2]
Phase I/II clinical trials involving retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells, for the treatment of severe myopia were approved in February 2013. [ 14 ] ViaCyte Human stem cell-derived beta cells for the treatment of Diabetes Clinical Trial
On November 22, 2010, the company announced that it had received approval from the U.S. Food and Drug Administration (FDA) to initiate the first human clinical trial using embryonic stem cells to treat retinal diseases. [11] A preliminary report of the trial published in 2012, [12] and a follow-up article was published in February 2015. [13]
At least 13 clinical trials were registered to treat AMD alone as of November 2016, the article authors write. But anecdotes like these bolster those who counsel restraint when it comes to stem cells.
Retinal implants are being developed by a number of private companies and research institutions, and three types are in clinical trials: epiretinal (on the retina), subretinal (behind the retina), and suprachoroidal (between the choroid and the sclera). The implants introduce visual information into the retina by electrically stimulating the ...
Masayo Takahashi (高橋 政代, Takahashi Masayo, born June 23, 1961) is a Japanese medical physician, ophthalmologist and stem cell researcher.. Takahashi serves as a project research leader at the Riken Center for Developmental Biology in Kobe focusing on the clinical application of iPS Cell (induced Pluripotent Stem Cell) technology on macular degeneration.
The retina of the human eye contains photoreceptive cells called cones that allow color vision. A normal trichromat possesses three different types of cones to distinguish different colors within the visible spectrum. The three types of cones are designated L, M, and S cones, each containing an opsin sensitive to a different portion of the ...
In October 2011, the first clinical trial was announced for the treatment of choroideremia. [12] Dr. Robert MacLaren of the University of Oxford, who lead the trial, co-developed the treatment with Dr. Miguel Seabra of the Imperial College, London. This Phase 1/2 trial used subretinal AAV to restore the REP gene in affected patients. [13]
Ads
related to: retinal stem cell clinical trials